4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001209191-23-016063
Chief Financial Officer sold 1,894 shares at an average $12.45 ($23,579)
- Chief Financial Officer acquired 6,450 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Balthaser Kevin Chief Financial Officer | 2023-03-01 | Option exercise | +1,475 | 2,175 | D | ||
| Balthaser Kevin Chief Financial Officer | 2023-03-01 | Option exercise | +1,100 | 3,275 | D | ||
| Balthaser Kevin Chief Financial Officer | 2023-03-01 | Option exercise | +2,375 | 5,650 | D | ||
| Balthaser Kevin Chief Financial Officer | 2023-03-02 | Sale | −1,000 | $12.29 | $12,289 | 4,650 | D |
| Balthaser Kevin Chief Financial Officer | 2023-03-02 | Option exercise | +1,500 | 6,150 | D | ||
| Balthaser Kevin Chief Financial Officer | 2023-03-03 | Sale | −894 | $12.63 | $11,290 | 5,256 | D |
| Derivatives | |||||||
| Balthaser Kevin Chief Financial Officer | 2023-03-01 | Option exercise · Restricted Stock Units | −1,475 | 0 | D | ||
| Balthaser Kevin Chief Financial Officer | 2023-03-01 | Option exercise · Restricted Stock Units | −1,100 | 2,200 | D | ||
| Balthaser Kevin Chief Financial Officer | 2023-03-01 | Option exercise · Restricted Stock Units | −2,375 | 7,125 | D | ||
| Balthaser Kevin Chief Financial Officer | 2023-03-02 | Option exercise · Restricted Stock Units | −1,500 | 1,500 | D | ||
| Open-market sales · 1,894 sh · avg $12.45 · $23,579 | |||||||
Loading xslF345X03/doc4.xml…